Lungs News and Research

RSS

New tool combines drugs to target kinase dependency in cancer

Targeted therapies attack a cancer's genetic sensitivities. However, it can be difficult to discover the genetics driving a patient's cancer, and the effects of drugs designed to target a genetic abnormality often go beyond their intended target alone. The result is threefold: sometimes a drug is prescribed to treat a target that proves to be irrelevant to the disease, sometimes an existing drug could be used to treat a cancer for which there is no approved targeted therapy, and sometimes a combination of targeted treatments could be used to simultaneously silence more than one genetic cause of a patient's cancer.

29 Jul 2015

Moerae announces initiation of second MMI-0100 Phase 1 clinical trial for pulmonary disorders

Moerae Matrix Inc. announced today the initiation of its second Phase 1 clinical trial with MMI-0100, a first-in-class inhibitor of MAPKAP kinase 2 (MK2) that is being developed for pulmonary disorders characterized by inflammation and fibrosis. The study, conducted in the United Kingdom, is a double-blind, two-way cross-over design lipopolysaccharide (LPS) challenge study further evaluating the safety and tolerability of MMI-0100 when given via inhalation to healthy subjects who smoke.

29 Jul 2015

Two-step regimen of experimental MERS vaccines show promise in mice

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. Vaccinated mice produced broadly neutralizing antibodies against multiple strains of the MERS coronavirus (MERS-CoV), while vaccinated macaques were protected from severe lung damage when later exposed to MERS-CoV.

29 Jul 2015

Moffitt researchers find cancer healthcare disparities in LGBTQ community

The Lesbian, Gay, Bisexual, Transgender/Transsexual, Queer/Questioning (LGBTQ) community is a growing and medically-underserved minority population in the United States, with 3 to 12 percent of the population estimated to identify as LGBTQ.

29 Jul 2015

Researchers develop dynamic functional mouse model for lung injury repair

Researchers at Children's Hospital Los Angeles and The Saban Research Institute of CHLA have created a dynamic functional mouse model for lung injury repair, a tool that will help scientists explain the origins of lung disease and provide a system by which new therapies can be identified and tested.

29 Jul 2015

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has engaged the services of a specialty specimen management clinical research organization, Global Specimen Solutions, Inc., to support initial U.S. market entry of its NuQ colorectal cancer tests.

28 Jul 2015

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

Scientists reveal potential therapeutic approach to idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis is a very aggressive form of pulmonary fibrosis and has a particularly poor prognosis. This fatal disease, for which so far no causal therapies exist, is characterized by a massive deposition of connective and scar tissue in the lung, which leads to a progressive loss of lung function and ultimately death.

28 Jul 2015

Biologists identify genetic mechanisms behind anti-inflammatory impact of cortisone

There's no time to lose when an emergency doctor diagnoses „Shock lung!" at the accident scene. What physicians know as "acute lung injury" (ALI) otherwise leads to death by suffocation without immediate treatment.

25 Jul 2015

Organ donor honored at Reagan UCLA Medical Center

Two years ago, Rachel Greenberg went out to run a few errands. While she was gone, her husband Glenn suffered a massive brain hemorrhage. He was immediately taken to Ronald Reagan UCLA Medical Center where physicians explained he had suffered the worst kind of brain bleed.

25 Jul 2015

ALCF to honor Fred R. Hirsch with 2015 Addario Lectureship Award for lung cancer research

The Bonnie J. Addario Lung Cancer Foundation will honor Fred R. Hirsch, M.D., Ph.D., with the 2015 Addario Lectureship Award for his continued leadership and expertise in lung cancer treatment and research. Dr. Hirsch, CEO of the International Association for the Study of Lung Cancer, will receive the award at the 16th International Lung Cancer Congress held on July 30 – August 1 in Huntington Beach, California.

25 Jul 2015

Moffitt researchers develop genetic test that analyzes sensitivity of tumors to radiation therapy

Recent advances in the understanding of cancer have led to more personalized therapies, such as drugs that target particular proteins and tests that analyze gene expression patterns in tumors to predict a patient's response to therapy.

24 Jul 2015

Mayo Clinic researchers study HDAC inhibitors to find effective treatments for anaplastic thyroid cancer

In their bid to find the best combination of therapies to treat anaplastic thyroid cancer (ATC), researchers on Mayo Clinic's Florida campus demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal.

24 Jul 2015

Smoke-free policy can improve living environment for apartment dwellers

Adopting a smoke-free policy can improve the living environment for apartment dwellers while reducing maintenance costs, according to a survey of multiunit housing owners and operators.

23 Jul 2015

Researchers develop dynamic smart drug that targets site-specific inflammation

Ben-Gurion University of the Negev and University of Colorado researchers have developed a dynamic "smart" drug that targets inflammation in a site-specific manner and could enhance the body's natural ability to fight infection and reduce side effects.

23 Jul 2015

Additional radiation to surrounding lymph nodes provides added benefit to breast cancer patients

A study has found no increase in overall survival but a reduction in breast cancer recurrence when additional radiation is given to the lymph nodes as well as the standard treatment of whole-breast irradiation after breast-conserving surgery.

23 Jul 2015

Scientists report new way to mimic the body's natural approach to programming stem cells to treat muscular dystrophy

Stem cells hold great potential for addressing a variety of conditions from spinal cord injuries to cancer, but they can be difficult to control. Scientists are now reporting in the journal ACS Nano a new way to mimic the body's natural approach to programming these cells.

23 Jul 2015

More people turn to popular new blood thinners for atrial fibrillation treatment

More adults than ever are visiting their doctors' offices for a prescription to treat atrial fibrillation, according to a study led by the University of Michigan Frankel Cardiovascular Center.

23 Jul 2015

Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

AstraZeneca today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib.

23 Jul 2015

Lungs News and Research

New tool combines drugs to target kinase dependency in cancer

Moerae announces initiation of second MMI-0100 Phase 1 clinical trial for pulmonary disorders

Two-step regimen of experimental MERS vaccines show promise in mice

Moffitt researchers find cancer healthcare disparities in LGBTQ community

Researchers develop dynamic functional mouse model for lung injury repair

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

Scientists reveal potential therapeutic approach to idiopathic pulmonary fibrosis

Biologists identify genetic mechanisms behind anti-inflammatory impact of cortisone

Organ donor honored at Reagan UCLA Medical Center

ALCF to honor Fred R. Hirsch with 2015 Addario Lectureship Award for lung cancer research

Moffitt researchers develop genetic test that analyzes sensitivity of tumors to radiation therapy

Mayo Clinic researchers study HDAC inhibitors to find effective treatments for anaplastic thyroid cancer

Smoke-free policy can improve living environment for apartment dwellers

Researchers develop dynamic smart drug that targets site-specific inflammation

Additional radiation to surrounding lymph nodes provides added benefit to breast cancer patients

Scientists report new way to mimic the body's natural approach to programming stem cells to treat muscular dystrophy

More people turn to popular new blood thinners for atrial fibrillation treatment

Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News